« Off-Label » Drug Use – Ethical Challenges - Case Study - AVASTIN®

Daniel Constantin Branisteanu, Mihnea Munteanu, Daciana Elena Branisteanu, Horia Tudor Stanca, Andreea Moraru, Florian Balta

Abstract


« Off-label » administration of certain drugs has represented a common practice in medicine in the latest decades. Even if this attitude can be sanctioned with full responsibility transfer to the prescribing doctor, there is no law to punish this kind of practice if, from ethical point of view, the main purpose was to offer the best therapeutic option according to a significantly clinic experience and the patient has been correctly informed and consented about the status of the therapy, risks and advantages.

In particular, in ophthalmology, bevacizumab (AVASTIN®) is widely used « off-label » since 2005, even though not approved for intravitreal injections, main reasons being similar efficacy and significantly lower costs as compared to approved drugs. In Romania, « off-label » use of bevacizumab has started in 2007 and, until recently, has represented the only chance for patients with certain invalidating eye conditions. Even if, starting this year aflibercept (EYLEA®) is officially available, « off-label » treatments with bevacizumab are expected to maintain a significant percentage until the Health Insurance will reimburse, at least in part, much higher costs for using approved drugs.              

Key Words:  « off-label » drugs, bevacizumab, intravitreal use; 


Full Text:

PDF

References


Randall S. Stafford. "Regulating Off-Label Drug Use — Rethinking the Role of the FDA". N Engl J Med 358 (14): 1427–1429.

Nielsen NN. Speaker AMA address to 210th Meeting of the House of Delegates American Medical Association “support of coverage for off label drug usage” 153rd Annual Meeting; Sunday June 12, 2004; Grand Ballroom Hyatt Regency Chicago USA. 2004.

James M. Beck & Elizabeth D. Azari. FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions. Issue: 53 Food and Drug Law Journal 71-104 (1998.

Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–6.

Zuberbieret et all, 3rd International Consensus Meeting on Urticaria, Allergy, 2009, 64,1427-1443.

GMC | Good practice in prescribing medicines - guidance for doctors". Gmc-uk.org. 2007-02-16. Retrieved 2011-11-21.

Sengupta N, Caballero S, Mames RN, Butler JM, Scott EW, Grant MB. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest Ophthalmol Vis Sci. Nov 2003;44(11):4908-13.

Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. Jun 1992;99(6):933-43.

United Nations. World Population to 2300. New York, NY, 24 March 2004.

Ferrara N, Hillan KJ, Novotny W. Review Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005 Jul 29; 333.

Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab plus irnotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

Beer PM, Wong SJ, Hammad AM, Falk NS, O′Malley MR, Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina. 2006;26:871–6.

Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GH. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013; 97(4):454-459.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388-98.

Prof Usha Chakravarthy PhD, Prof Simon P Harding MD , Chris A Rogers PhD , Susan M Downes MD , Prof Andrew J Lotery MD , Lucy A Culliford PhD , Prof Barnaby C Reeves DPhil , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet, Volume 382, Issue 9900, Pages 1258 - 1267, 12 October 2013.

D Wong and G Kyle. Some ethical considerations for the “off‐label” use of drugs such as Avastin. Br J Ophthalmol. 2006 October; 90(10): 1218–1219.

Klein RM, Klein RB. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration. Retina. 2007 Nov-Dec;27(9):1163-5.

Jansen, Rita-Marié and Gouws, Chris. Clinical, legal and ethical implications of the intra-ocular (off-label) use of bevacizumab (Avastin): a South African perspective. SAMJ, S. Afr. med. j. [online]. 2009, vol.99, n.6, pp. 446-449. ISSN 0256-9574.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2015 Revista Romana de Bioetica